Vyome's VT-1953 Achieves Primary Endpoints in Phase 2 Trial for Malignant Fungating Wounds
核心洞察
Vyome's VT-1953 (搜索) topical gel demonstrated statistically significant improvements in malodor (P=0.002) and quality of life (P=0.0256) in patients with malignant fungating wounds (搜索) during a 14-day Phase 2 trial.
The first-in-class immunomodulator also showed significant pain reduction (P=0.002) and was well-tolerated with no new safety concerns observed.
Based on these positive results, Vyome plans to advance VT-1953 (搜索) into a pivotal Phase III study following FDA discussions to target a $1 billion addressable market opportunity.
Vyome Holdings (搜索), Inc. (Nasdaq: HIND) announced positive final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 (搜索) topical gel in patients with malignant fungating wounds (搜索) (MFW). The first-in-class immunomodulator achieved both its primary and secondary endpoints, positioning the company to advance into Phase III development targeting a $1 billion addressable market.
Primary and Secondary Endpoint Success
VT-1953 (搜索) treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wounds (搜索), the study's primary endpoint (P = 0.002). Patients treated with VT-1953 achieved statistically significant improvement from severe bad smell at baseline to much milder smell within 14 days of treatment. The improvement was statistically significant compared with vehicle-treated patients (P = 0.0015), with benefits observed as early as Day 7 (P = 0.015).
The secondary endpoint of patient-reported impact of bad smell on quality of life showed statistically significant improvement (P = 0.0256) compared to vehicle-treatment by Day 14. Additionally, patients treated with VT-1953 (搜索) reported clinically significant improvement in pain symptoms by Day 14 (P = 0.002 compared with baseline; P = 0.0026 vs vehicle-treated patients).
Safety Profile and Tolerability
VT-1953 (搜索) was well-tolerated by patients, with no new safety concerns observed during the 14-day treatment period. The topical gel formulation demonstrated an acceptable safety profile across all study participants.
Addressing Significant Unmet Medical Need
Malignant fungating wounds (搜索) represent a debilitating condition that occurs in 5-14% of advanced cancer (搜索) patients. The condition affects over 693,000 patients with advanced cancer in the US alone and approximately 10 million globally. Cancer cells break through the skin and cause chronic wounds that are extremely distressing to patients, creating a high burden of symptoms including extreme bad smell, severe pain, feelings of shame, low self-esteem, and social isolation.
"These are exciting results for Vyome, both in our primary and secondary endpoints. Inflammation is one of the greatest problems in the world today, and our study on malignant fungating wounds (搜索) showed that those who received our drug VT-1953 (搜索) had significant and rapid improvements in symptoms, quality of life, and emotional and physical functions," said Dr. Shiladitya Sengupta, co-founder and director of Vyome and Associate Professor of Medicine at Harvard Medical School.
Path to Market Authorization
Based on these positive Phase 2 results, Vyome plans to advance VT-1953 (搜索) into a pivotal study following discussions with the FDA to seek approval. The company aims to enter the $1 billion potential addressable market as the only anticipated approved solution for malignant fungating wounds (搜索).
"These positive results reinforce the potential of VT1953, and we are now preparing to engage with the FDA to design and initiate a pivotal Phase III clinical study in 2026," stated Venkat Nelabhotla, CEO of Vyome. "Over the past several months, we have strengthened our team with top-tier clinical, regulatory, and scientific leaders who bring deep experience in advancing differentiated therapies."
Financial Position and Market Context
Vyome remains well capitalized through 2026, allowing the company to advance VT1953 as a potentially orphan designation program within its broader chronic immune-inflammation portfolio. The global immune-inflammatory market size is expected to reach USD 431.11 billion by 2033, growing at a CAGR of 8.2% from $212 billion in 2024.